Effect of adenine arabinoside on cytomegalovirus infections.
D000328:Adult; D001089:Arabinose / Q000633:toxicity; D001927:Brain Diseases / Q000382:microbiology; D002478:Cells, Cultured; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000150:complications / Q000151:congenital / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007223:Infant; D007231:Infant, Newborn; D007244:Infectious Mononucleosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010614:Pharynx / Q000382:microbiology; D011684:Purine Nucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012463:Saliva / Q000382:microbiology; D014556:Urine / Q000382:microbiology
D011684:Purine Nucleosides; D001089:Arabinose